Study Overview and Unmet Need

Light chain (AL) amyloidosis is a rare blood disorder in which abnormal plasma cells produce light chain proteins that deposit in organs, damaging the heart, kidneys, and liver. The current first-line standard treatment, daratumumab (Darzalex Faspro)-VCd, demonstrated a hematologic complete response rate (hCR) of 59.5% and an overall survival hazard ratio (HR) of 0.62 (P=0.0121) in the ANDROMEDA Phase 3 final analysis. However, there are no approved targeted therapies for patients with relapsed/refractory disease. Patients with t(11;14) translocation, which accounts for 50-60% of all AL amyloidosis cases, exhibit significant BCL-2 overexpression, highlighting the urgent need for a personalized treatment strategy targeting this molecule.

Clinical Design and Progress

NCT05451771 is an open-label Phase 1/2 multi-center trial led by Dr. Rajshekhar Chakraborty at Columbia University, with Genentech as the industry sponsor. In the Phase 1 dose-escalation phase, four cohorts will explore venetoclax (200-400mg) alone and in combination with dexamethasone (10-20mg) once weekly to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). In Phase 2, the determined dose will be randomly compared to a control group (daratumumab, pomalidomide, bendamustine, and ixazomib, as selected by the investigator), with a target enrollment of 53 patients across three centers. The primary completion date is expected to be September 2026.

Potential Indicated by Prior Data

Venetoclax, co-marketed by AbbVie (ABBV) and Roche (RHHBY), is a BCL-2 selective inhibitor approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) under the brand name Venclexta, generating global sales of approximately USD 2.79 billion in 2025. Retrospective studies of relapsed/refractory AL amyloidosis patients with t(11;14) translocation have reported impressive hematologic response rates of 81-97% and complete response rates of 54-78%. An analysis by the French Amyloidosis Network showed a response rate of 97% when switching to venetoclax after daratumumab failure, and long-term follow-up of 22 patients confirmed 95% hematologic response and sustained remission.

Competitive Landscape and Market Outlook

The AL amyloidosis treatment market was valued at approximately USD 2.5-4.4 billion in 2025 and is projected to grow at a compound annual growth rate of 7-9%. BeiGene's next-generation BCL-2 inhibitor, sonrotoclax (BGB-11417), which targets the same t(11;14) target, has demonstrated an overall response rate (ORR) of 84% in a Phase 1b/2 trial for multiple myeloma and has also entered a clinical trial (NCT07335887) for AL amyloidosis. Prothena's birtamimab is undergoing a Phase 3 trial in Mayo Stage IV patients, utilizing an amyloid fibril removal mechanism. With daratumumab-VCd receiving FDA full approval in November 2025 and establishing a first-line standard of care, a key question is whether the combination of venetoclax can establish a new standard in the relapsed/refractory setting. The release of the Phase 1 results in September 2026 will be a pivotal moment in determining the competitive landscape for the entire BCL-2 inhibitor class.

Why This Matters

T(11;14) positive AL amyloidosis accounts for 50-60% of all patients, representing a significant unmet need as there are no approved targeted therapies for relapsed/refractory patients. If venetoclax, which has demonstrated hematologic response rates of 81-97% in prior data, confirms similar efficacy and safety in the prospective Phase 1/2 trial, it will directly translate into an expansion of the indications for Venclexta, which generated annual sales of USD 2.79 billion. With BeiGene's sonrotoclax entering a clinical trial for AL amyloidosis and daratumumab-VCd securing full approval, the Phase 1 MTD data and Phase 2 randomized comparison results will serve as leading indicators for investors to assess the potential for this class to enter the AL amyloidosis indication.